Posted in | News | Business

BASF Considers Options After Engelhard Takeover Bid was Rejected

BASF is considering all its options after Engelhard’s Board of Directors rejected an increased cash offer of $38 per share proposed by BASF, as part of a negotiated merger transaction, and elected instead to pursue a partial share buyback plan.

Following a preliminary review of Engelhard’s proposed transaction, BASF continues to believe that its fully financed, all-cash offer provides higher value and greater certainty to Engelhard’s stockholders over and above that achievable through the Engelhard partial share buyback plan. BASF’s offer would provide cash to Engelhard’s stockholders for 100 percent of their shares within three weeks after reaching a negotiated merger agreement. By contrast, Engelhard’s proposal carries significantly higher execution, timing and realization risks.

After reviewing non-public information provided by Engelhard, BASF made a $38 per share all-cash offer, conditional on a negotiated transaction. The revised offer was presented to Engelhard’s Board of Directors on April 19, 2006, together with a proposal for a merger agreement.

As stated during Engelhard’s investor conference call today, no party participating in Engelhard’s robust process valued Engelhard at greater than $38 per share or offered an attractive proposal for any part of the business, notwithstanding full access to non-public information and access to management.

BASF’s current tender offer of $37 per share is scheduled to expire at 5:00 p.m., New York City time, on Friday, April 28, 2006, unless the offer is further extended.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.